ING Groep NV Sells 5,235 Shares of Edwards Lifesciences Co. (NYSE:EW)

ING Groep NV cut its position in shares of Edwards Lifesciences Co. (NYSE:EW) by 6.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 75,330 shares of the medical research company’s stock after selling 5,235 shares during the period. ING Groep NV’s holdings in Edwards Lifesciences were worth $5,577,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. FSA Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at approximately $30,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Edwards Lifesciences in the 4th quarter valued at approximately $30,000. Prospera Private Wealth LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter valued at approximately $32,000. Avior Wealth Management LLC lifted its stake in shares of Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 308 shares during the last quarter. Finally, JFS Wealth Advisors LLC lifted its stake in shares of Edwards Lifesciences by 31.1% in the 3rd quarter. JFS Wealth Advisors LLC now owns 700 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 166 shares during the last quarter. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Trading Down 2.0 %

Shares of NYSE:EW opened at $73.25 on Friday. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The business’s fifty day simple moving average is $72.85 and its 200-day simple moving average is $69.94. The company has a market capitalization of $43.20 billion, a PE ratio of 10.51, a P/E/G ratio of 4.82 and a beta of 1.10. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, equities research analysts predict that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

EW has been the subject of several analyst reports. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and raised their price objective for the company from $75.00 to $90.00 in a research note on Thursday, January 30th. Bank of America raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their price objective for the company from $82.00 to $90.00 in a research note on Monday, December 16th. Morgan Stanley increased their price target on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a report on Wednesday, February 12th. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a report on Monday, October 28th. Finally, Canaccord Genuity Group increased their price target on Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a report on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $79.95.

Insider Transactions at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 6,500 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.75, for a total value of $492,375.00. Following the completion of the sale, the vice president now owns 46,936 shares of the company’s stock, valued at $3,555,402. This trade represents a 12.16 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Scott B. Ullem sold 11,250 shares of the firm’s stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the sale, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at $2,315,301.36. The trade was a 26.91 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 26,489 shares of company stock valued at $2,002,829 in the last quarter. 1.29% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.